{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:24:32Z","timestamp":1759937072183},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4425","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T22:04:23Z","timestamp":1443650663000},"page":"2467-2470","source":"Crossref","is-referenced-by-count":4,"title":["Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure"],"prefix":"10.2169","volume":"54","author":[{"given":"Fumihiko","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Rumoi City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Rumoi City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Rumoi City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Cardiovascular, Respiratory and Neurology Division, Department of Internal Medicine, Asahikawa Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 9: 133-142, 1998.","DOI":"10.1681\/ASN.V91133"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. González R, Morales E, Segura J, Ruilope LM, Praga M. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant 25: 3266-3272, 2010.","DOI":"10.1093\/ndt\/gfq143"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Beutler JJ, Koomans HA. Malignant hypertension: still a challenge. Nephrol Dial Transplant 12: 2019-2023, 1997.","DOI":"10.1093\/ndt\/12.9.2019"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37: 253-390, 2014.","DOI":"10.1038\/hr.2014.20"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. van den Born BJ, Koopmans RP, van Montfrans GA. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 20: 900-906, 2007.","DOI":"10.1016\/j.amjhyper.2007.02.018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Naruse M, Demura H, Naruse K, Tanabe A, Yoshimoto T, Seki T. Renin\/angiotensin\/aldosterone system in malignant hypertension. Intern Med 36: 669-671, 1997.","DOI":"10.2169\/internalmedicine.36.669"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rafic K, Hitomi H, Nakano D, Nishiyama A. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci 115: 1-7, 2011.","DOI":"10.1254\/jphs.10R07CR"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 81: 955-968, 2012.","DOI":"10.1038\/ki.2011.505"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nonaka K, Ubara Y, Sumida K, et al. Clinical and pathological evaluation of hypertensive emergency-related nephropathy. Intern Med 52: 45-53, 2013.","DOI":"10.2169\/internalmedicine.52.7398"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021-1026, 2003.","DOI":"10.1161\/01.HYP.0000067463.13172.EA"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 1831-1838, 2003.","DOI":"10.1161\/01.CIR.0000091405.00772.6E"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.","DOI":"10.1056\/NEJMoa030207"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Oka K, Hayashi K, Nakazato T, Suzuwa T, Fujiwara K, Saruta T. Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration. Intern Med 36: 700-704, 1997.","DOI":"10.2169\/internalmedicine.36.700"},{"key":"14","unstructured":"14. Vaclavic J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57: 1069-1075, 2011."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1: 940-951, 2006.","DOI":"10.2215\/CJN.00240106"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One 6: e26904, 2011.","DOI":"10.1371\/journal.pone.0026904"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/19\/54_54.4425\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T13:58:32Z","timestamp":1653227912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/19\/54_54.4425\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":16,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4425","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}